SCHEMBL4020347

SCHEMBL4020347

Cc1cccc(C2C(C(=O)c3ccccc3)CN(CC(=O)N(C)C)CC2C(=O)c2ccccc2)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.37
GRIN2B Q13224 2/20 0.36
RORC P51449 1/20 0.35
ABCB1 P08183 2/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KCNH2 Q12809 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024526 1.00 KIF11 (0.37) KIF11GRIN2BRORCABCB1LMNA
SCHEMBL4020344 1.00 KIF11 (0.37) KIF11GRIN2BRORCABCB1LMNA
SCHEMBL4776575 0.96 KIF11 (0.39) KIF11GRIN2BRORCMEN1KMT2A
SCHEMBL4776569 0.96 KIF11 (0.39) KIF11GRIN2BRORCMEN1KMT2A
SCHEMBL4025031 0.92 LMNA (0.37) GRIN2BRORCLMNAKDM4ENPC1
SCHEMBL4025032 0.92 LMNA (0.37) GRIN2BRORCLMNAKDM4ENPC1
SCHEMBL4024639 0.90 OPRM1 (0.36) KIF11RORCKCNH2
SCHEMBL4024642 0.90 OPRM1 (0.36) KIF11RORCKCNH2
SCHEMBL4021213 0.90 GRIN2B (0.38) KIF11GRIN2BRORCABCB1LMNA
SCHEMBL4021208 0.90 GRIN2B (0.38) KIF11GRIN2BRORCABCB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KIF11 3745/4885GRIN2B 4170/4885RORC 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.